急冠脉综合征治疗指南解读课件.ppt

Many patients with UA/NSTEMI have chronic stable angina at hospital discharge. The management of the patient with stable CAD is detailed in the ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina)1. The following are recommendations (Class I) for pharmacotherapy to prevent death and myocardial infarction: ASA 75 to 325 mg per d in the absence of contraindications (level of evidence: A) clopidogrel 75 mg daily (in the absence of contraindications), when ASA is not tolerated because of hypersensitivity or gastrointestinal intolerance. (level of evidence: AB) the combination of ASA and clopidogrel for 9 months after UA/NSTEMI. (level of evidence: B) Beta-blockers in the absence of contraindications (level of evidence: B) Lipid-lowering agents and diet in post-ACS patients, including postrevascularization patients, with lowdensity lipoprotein (LDL) cholesterol of greater than 130 mg per dL (level of evidence : A) Lipid-lowering agents if LDL cholesterol level after diet is greater than 100 mg per dL. (level of evidence : B) ACEIs for patients with CHF, LV dysfunction (EF less than 0.40), hypertension, or diabetes. (level of evidence: A).2 Reference: 1. Gibbons RJ et al. J Am Coll Cardiol 1999; 33: 2092–7. 2. Braunwald E et al. American College of Cardiology (ACC) and the American Heart Association (AHA) Guidelines, USA: ACC/AHA; 2002. CREDO is a randomized, double-blind, controlled trial of early and long-term (1 year) dual with 波立维 on top of standard therapy including ASA for percutaneous coronary intervention. This slide-kit covers the results of the CREDO Trial, which were presented during the Late Breaking Trials Session on Monday November 18, 2002 at the Annual Scientific Sessions of the American Heart Association, held in Chicago, Illinois, and published in the Wednesday November 20 issue of the Journal of the American Medical Association (JAMA). Reference: Steinhubl SR, Berger PB, Tift Mann III J, et al. JAMA, November 20, 2